In the quest to outshine the broader market, stock pickers diligently seek out stocks with the potential for superior performance. Making the right choices can significantly elevate your wealth.
The closing price of Cytokinetics Inc (NASDAQ: CYTK) was $35.25 for the day, up 0.31% from the previous closing price of $35.14. In other words, the price has increased by $0.31 from its previous closing price. On the day, 1.04 million shares were traded. CYTK stock price reached its highest trading level at $35.59 during the session, while it also had its lowest trading level at $34.67.
Ratios:
Our analysis of CYTK’s different ratios will help us gain a deeper understanding of the company. For the most recent quarter (mrq), Quick Ratio is recorded 5.99 and its Current Ratio is at 5.99.
On April 24, 2025, Barclays started tracking the stock assigning a Overweight rating and target price of $55. On February 07, 2025, Citigroup started tracking the stock assigning a Buy rating and target price of $86.Citigroup initiated its Buy rating on February 07, 2025, with a $86 target price.
Insider Transactions:
Also, insider trades can serve as a great indicator of what management thinks about the future direction of a stock’s price. A recent insider transaction in this stock occurred on Aug 05 ’25 when Malik Fady Ibraham sold 2,000 shares for $36.34 per share. The transaction valued at 72,680 led to the insider holds 140,610 shares of the business.
Blum Robert I sold 5,000 shares of CYTK for $182,250 on Jul 29 ’25. The President & CEO now owns 388,108 shares after completing the transaction at $36.45 per share. On Jul 22 ’25, another insider, Malik Fady Ibraham, who serves as the EVP Research & Development of the company, sold 2,000 shares for $37.47 each. As a result, the insider received 74,940 and left with 140,610 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, CYTK now has a Market Capitalization of 4209801728 and an Enterprise Value of 4182049024. For the stock, the TTM Price-to-Sale (P/S) ratio is 219.03. Its current Enterprise Value per Revenue stands at 217.611 whereas that against EBITDA is -7.52.
Stock Price History:
The Beta on a monthly basis for CYTK is 0.63, which has changed by -0.36816633 over the last 52 weeks, in comparison to a change of 0.18634176 over the same period for the S&P500. Over the past 52 weeks, CYTK has reached a high of $59.39, while it has fallen to a 52-week low of $29.31. The 50-Day Moving Average of the stock is 1.48%, while the 200-Day Moving Average is calculated to be -17.19%.
Shares Statistics:
CYTK traded an average of 1.54M shares per day over the past three months and 1192670 shares per day over the past ten days. A total of 119.22M shares are outstanding, with a floating share count of 116.80M. Insiders hold about 2.20% of the company’s shares, while institutions hold 115.76% stake in the company. Shares short for CYTK as of 1752537600 were 15929741 with a Short Ratio of 10.34, compared to 1749772800 on 14005230. Therefore, it implies a Short% of Shares Outstanding of 15929741 and a Short% of Float of 17.4.
Earnings Estimates
Investors are keenly observing as 17.0 analysts analyze and rate the current performance of Cytokinetics Inc (CYTK) in the stock market.The consensus estimate for the next quarter is -$1.7, with high estimates of -$1.7 and low estimates of -$1.7.
Analysts are recommending an EPS of between -$1.22 and -$6.35 for the fiscal current year, implying an average EPS of -$5.52. EPS for the following year is -$5.38, with 15.0 analysts recommending between -$2.88 and -$7.31.
Revenue Estimates
A total of 18 analysts have provided revenue estimates for CYTK’s current fiscal year. The highest revenue estimate was $88.79M, while the lowest revenue estimate was $1.58M, resulting in an average revenue estimate of $23.83M. In the same quarter a year ago, actual revenue was $18.47MBased on 16 analysts’ estimates, the company’s revenue will be $166.23M in the next fiscal year. The high estimate is $368M and the low estimate is $48.35M.
